BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

720 related articles for article (PubMed ID: 18400579)

  • 1. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.
    Lee WL; Cheng MH; Chao HT; Wang PH
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):24-31. PubMed ID: 18400579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen, raloxifene and the prevention of breast cancer.
    Bentrem DJ; Craig Jordan V
    Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Additional effect of SERM: mammary gland].
    Kurebayashi J
    Clin Calcium; 2004 Oct; 14(10):47-51. PubMed ID: 15577131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
    Johnston SR
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Selective estrogen receptor modulators (SERMs)].
    Matsumoto T
    Clin Calcium; 2006 Sep; 16(9):1520-25. PubMed ID: 16951478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Selective estrogen receptors modulators (SERMs): biochemistry, pharmacology, and clinical use in gynecology].
    Terán Dávila J; Teppa Garrán AD
    Ginecol Obstet Mex; 2005 Aug; 73(8):424-35. PubMed ID: 16304968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
    Lewis JS; Jordan VC
    Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of hormone-related cancers: breast cancer.
    Dunn BK; Wickerham DL; Ford LG
    J Clin Oncol; 2005 Jan; 23(2):357-67. PubMed ID: 15637398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raloxifene (Evista) for breast cancer prevention in postmenopausal women.
    Med Lett Drugs Ther; 2006 May; 48(1234):37. PubMed ID: 16685245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
    Jordan VC; O'Malley BW
    J Clin Oncol; 2007 Dec; 25(36):5815-24. PubMed ID: 17893378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy.
    Labrie F
    Nat Clin Pract Endocrinol Metab; 2007 Aug; 3(8):584-93. PubMed ID: 17643129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
    Pinkerton JV; Goldstein SR
    Menopause; 2010; 17(3):642-53. PubMed ID: 20107426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
    Vogel VG
    Ann N Y Acad Sci; 2006 Nov; 1089():127-42. PubMed ID: 17261762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective estrogen receptor modulators and postmenopausal health.
    Roe EB; Chiu KM; Arnaud CD
    Adv Intern Med; 2000; 45():259-78. PubMed ID: 10635051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
    Martino S; Cauley JA; Barrett-Connor E; Powles TJ; Mershon J; Disch D; Secrest RJ; Cummings SR;
    J Natl Cancer Inst; 2004 Dec; 96(23):1751-61. PubMed ID: 15572757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemoprevention of breast cancer. Clinical trials in pharmacological prevention].
    Ricart JJ
    Medicina (B Aires); 2004; 64(1):66-72. PubMed ID: 15034961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.
    Dunn BK; Ford LG
    Eur J Cancer Prev; 2007 Jun; 16(3):232-42. PubMed ID: 17415094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.